Sara Kazmi is an Assistant Professor of English at the University of Pennsylvania, with affiliations in Comparative Literature and Literary Theory, and Gender, Sexuality, and Women's Studies. Her interdisciplinary research bridges literary studies, performance, and history to examine anticolonial and Marxist literary movements in South Asia. Focuses on Panjabi writers from India/Pakistan (1960s-70s) Co-editor of 'Digital Teaching Tools' for Revolutionary Papers PhD from University of Cambridge in Criticism and Culture Expertise in oral traditions, manuscript studies, and postcolonial resistance Research Interests explore how marginal literary traditions challenge nationalist and capitalist structures. Her work engages: Anticolonial print cultures Queer and trans theory in South Asian contexts Ghadar movement's transnational legacy Language politics and regional autonomy Archival studies and ethnographic methods Her publications demonstrate expertise in: Marxist literary radicalism Gendered reinterpretations of folk narratives Decolonial approaches to epidemiology and spatial studies
Søren Lundbye-Christensen is an Associate Professor and Biostatistician affiliated with the Clinical Institute at the Faculty of Health Sciences, Aalborg University, and Aalborg University Hospital in Denmark. He specializes in biostatistical support for medical research, with a strong emphasis on cardiovascular and epidemiological studies. His research interests include biostatistics, survival analysis, cohort studies, clinical epidemiology, and statistical modeling in public health. He has contributed to a wide array of healthcare research, particularly in cardiovascular diseases, cancer, maternal health, and infectious diseases. His methodological expertise spans time-to-event analysis, registry-based research, and interval-censored data modeling. The recent publications highlight a strong trend in applying advanced statistical methods to large-scale clinical and population-based datasets. His work often involves collaboration with medical researchers to derive prognostic models, validate clinical databases, and assess public health outcomes. Key themes include cardiovascular risk, fertility, cancer biomarkers, and implementation of medical training programs. Scientific Contributions and Recognition: Published over 320 research articles and datasets. Active contributor to methodological advancements in biostatistics. Regular peer reviewer, including for journals like the R Journal. Public engagement through media appearances on statistics and health. Academic Advising and Grants: Søren has supervised 31 student theses, formally serving as PhD supervisor for 14 theses and as a biostatistical advisor for 19 others, primarily in mathematics and statistics. He has participated in numerous research projects funded through institutional and national grants, including studies on seasonal disease trends, postoperative complications, and metabolic disease prediction. His work often involves interdisciplinary collaboration across medicine, public health, and data science. Labs and Research Teams: He is embedded in collaborative research networks at Aalborg University Hospital and Aalborg University, contributing statistical expertise to clinical research groups. He is involved in projects utilizing Danish national health registries and has contributed to the development and validation of clinical databases. His work supports both hypothesis-driven medical research and methodological innovation in biostatistics.
Ulrich Lächelt is an Assistant Professor in the Department of Pharmaceutical Sciences at the Faculty of Life Sciences. His research focuses on nanoparticle technology, drug delivery systems, and gene therapy, with a particular emphasis on CRISPR/Cas9 genome editing and RNA-based therapeutics. He leads a project on nanoformulations of prime editing ribonucleoproteins (2025–2029), aiming to advance precision medicine. His work contributes to UN Sustainable Development Goals, particularly in health and innovation. Research Interests: Nanoparticle design and material science CRISPR/Cas9 delivery systems siRNA and mRNA therapeutic formulations Cancer-targeted drug delivery Biomedical engineering applications Publications (2025–2023): Highlighted studies include dual pH-responsive CRISPR delivery systems and accelerated endosomal escape mechanisms. His work spans 40+ peer-reviewed articles, with recent trends focusing on xenopeptide carriers and tumor-targeted therapies. Grants & Projects: Current research funding includes a nanoformulations project (2025–2029). He actively collaborates on international initiatives, with recent presentations at global conferences on CRISPR delivery and gene editing strategies. Labs/Teams: Involved in interdisciplinary teams developing novel drug delivery platforms and screening tools for prime editor RNPs.
Pankaj Mehta is a Professor in the Department of Physics at Boston University, with additional affiliations in the Department of Biomedical Engineering. His research bridges statistical physics, theoretical biology, and interdisciplinary systems approaches. Key areas include ecological dynamics, synthetic biology, and the application of machine learning principles to biological systems. His work focuses on understanding emergent phenomena in biological systems, such as cell fate decisions, ecosystem stability, and signal processing in cellular networks. He has pioneered methods combining physics-based modeling with computational tools to study complex systems, including gene circuits, microbial communities, and cancer dynamics. Recent contributions highlight the use of order parameters for interpreting cellular states, geometric frameworks for ecological niches, and machine learning analogies to ecological principles. His interdisciplinary approach integrates experimental data with theoretical models to address questions in biomedicine, environmental science, and fundamental physics.
Sanjana Mudduluru is an Assistant Professor in the School of Computer Science at the University of Oklahoma (OU). She holds a BS from Jawaharlal Nehru Technological University (India), an MS in Data Science & Analytics, and a PhD in Computer Science, all from OU. Her research focuses on applying computer vision and machine learning to biomedical imaging, particularly in cancer research and medical diagnostics. She has extensive experience in software development and programming. Education: Ph.D., Computer Science, University of Oklahoma M.S., Data Science & Analytics, University of Oklahoma B.Tech, Computer Science, Jawaharlal Nehru Technological University Her research interests span machine learning, medical image processing, data analytics, and computer science education. She explores innovative deep learning models for medical image segmentation, classification, and synthetic data generation to enhance AI efficacy in healthcare. Recent work includes hybrid models for computer-aided diagnosis and self-supervised learning for rock image analysis. Awards: Dissertation Excellence Award (2023) Tomorrows Engineer Scholarship (2021–2022) CS Alumni Graduate Fellowship (2021–2022) Dr. Mudduluru has no listed advisees but has contributed to grants related to biomedical imaging research. She is affiliated with OU’s Devon Energy Hall and actively publishes in interdisciplinary fields blending computer science with healthcare applications.
Prim. Clin. Assoc. Prof. PD Dr. Dietmar Dammerer, MSc PhD is the head of the Clinical Department of Orthopaedics and Traumatology at Krems University Hospital, affiliated with Karl Landsteiner Private University of Health Sciences. He has been in this role since February 2022, leading the merger of orthopedics and traumatology into a unified clinical department. A dual-trained specialist, he is recognized for his expertise in endoprosthetics and tumor orthopedics, and actively promotes interdisciplinary collaboration and team-based medicine. His educational background includes a PhD in Musculoskeletal Sciences (2015), an MSc in Advanced Orthopaedics and Traumatology (2017), and board certification in both orthopedics and traumatology (2017, 2018), culminating in habilitation in 2019. He has received prestigious Traveling Fellowships from the European Hip Society and European Musculo-Skeletal Oncology Society. Dietmar Dammerer’s research focuses on orthopedic oncology, joint reconstruction, biomechanics, and minimally invasive surgery. His work emphasizes the integration of clinical inquiry with research to improve patient outcomes. Recent publications analyze pelvic sarcoma reconstruction, spinal metastases, cartilage repair techniques, and health disparities in sarcoma care. His 15 most recent articles reflect a strong trend in musculoskeletal oncology, surgical biomechanics, and evidence-based orthopedic practice, with frequent use of systematic reviews, retrospective studies, and multicenter collaborations. Topics include implant performance, surgical safety, and global access to specialized care. Scientific awards include: Traveling Fellow Stipendium from the European Hip Society (2018) Traveling Fellow Stipendium from the European Musculo-Skeletal Oncology Society (2020) He is deeply committed to mentoring and team development, emphasizing that medical success is measured by the success of one’s colleagues. He leads a research-active department that hosts international observers, conducts training courses for physicians across Europe, the Middle East, and Africa, and maintains a high rate of peer-reviewed publication. The department collaborates closely with the Departments of Biomechanics and Anatomy and Developmental Biology, reflecting a multidisciplinary research approach.
Jonathan Ellman is the Eugene Higgins Professor of Chemistry and Professor of Pharmacology at Yale University, with joint appointments in the Department of Chemistry and the Department of Pharmacology at the Yale School of Medicine. He is also affiliated with the Yale Cancer Center and the Developmental Therapeutics program. Education: PhD, Chemistry, Harvard University (1989) BS, Chemistry, MIT (1984) NSF Postdoctoral Fellow, University of California at Berkeley (1992) Dr. Ellman's research lies at the intersection of synthetic organic chemistry and biomedical science, focusing on the development of novel synthetic methodologies and their application to drug discovery. His work emphasizes catalysis, particularly in C–H activation and enantioselective synthesis, with a strong interest in sulfur-containing compounds such as sulfoximines and sulfilimines as bioactive motifs. His lab has pioneered methods for constructing complex amine and amide architectures with quaternary centers, which are valuable in medicinal chemistry. A recent focus includes targeting opioid receptors for pain therapeutics with reduced side effects. His research has led to over 350 publications and significant contributions to chemical biology and pharmaceutical sciences. His recent publications reveal a consistent focus on catalytic methodologies, sulfur chemistry, and computational drug design, particularly in targeting opioid receptors. Themes include enantioselective synthesis, C–H functionalization, and the exploration of underutilized heteroatom-containing functional groups in drug discovery. Scientific Awards and Honors: Member, American Academy of Arts and Sciences (2016) Yale Dylan Hixon ’88 Prize for Teaching Excellence in the Natural Sciences (2016) Herbert C. Brown Award for Creative Research in Synthetic Methods (2012) GlaxoSmithKline Chemistry Scholar Award (2010) Pedler Award, Royal Society of Chemistry (2010) Dr. Ellman has trained numerous researchers and maintains a highly collaborative research program, evidenced by frequent co-authorship with colleagues across Yale. His lab, accessible via ellman.chem.yale.edu , is part of Yale’s broader research ecosystem in chemical biology and therapeutics. He has received continuous grant support, particularly in the areas of synthetic methods development and translational chemical biology, although specific grants are not detailed in the text.
Sarah C. Hull, MD, MBE is an Associate Professor of Medicine (Cardiology) at Yale School of Medicine, where she serves as Associate Director of the Program for Biomedical Ethics and Cardiology Course Director. She is affiliated with the Department of Internal Medicine, Cardio-Oncology Program, Cardiovascular Imaging Program, and Yale Cancer Center. Education: AB, Biochemical Sciences, Harvard University (2003) MD, University of Pennsylvania School of Medicine (2008) MBE, University of Pennsylvania School of Medicine (2008) Residency, Hospital of the University of Pennsylvania (2011) Fellowship, Yale University School of Medicine (2014) Her research and scholarly work focus on bioethics in cardiology and public health, with key interests in end-of-life care, LVAD deactivation, shared decision-making in cardio-oncology, nutrition ethics, vaccine ethics, and reproductive health ethics. She advocates for integrating ethical frameworks into clinical cardiology practice and medical education. Her work often addresses moral uncertainty, physician-patient communication, and systemic inequities in healthcare access. Recent publications highlight trends in cardioethics , exploring AI's role in moral agency, ethical boundaries in medicine, and curriculum development for ethics training in cardiology. She also contributes to cardio-oncology research, particularly in predicting cardiovascular outcomes in cancer survivors using advanced imaging. Scientific Awards: Bohmfalk Prize for Teaching in Basic Sciences (2021) Sarah C. Hull is actively involved in medical education and ethics leadership. She advises on clinical ethics policy and collaborates with interdisciplinary teams across Yale. She has no listed advisees or grants in the provided text, but her role as Associate Director suggests mentorship and program leadership. She is part of research teams in cardio-oncology and ethics, contributing to collaborative publications. Labs and Teams: She collaborates with researchers in the Cardio-Oncology Program and the Program for Biomedical Ethics, and is a frequent co-author with experts in cardiology, neurology, and oncology at Yale.
Timothee Lionnet is an Associate Professor in the Department of Cell Biology at NYU Grossman School of Medicine. He holds a PhD from the University of Paris and completed postdoctoral training at Albert Einstein College of Medicine in Robert H Singer's lab. His research focuses on understanding how cells regulate gene expression through single-molecule imaging, bridging molecular-scale observations with cellular and tissue-level processes. Education: PhD in Paris, Postdoc at Einstein College of Medicine His work integrates live-cell imaging technologies, computational modeling, and systems genetics to investigate transcriptional dynamics, epigenetic regulation, and cellular responses to environmental cues. The Lionnet Lab develops novel tools to visualize gene activity in real time, aiming to uncover principles of robust gene expression programs and their role in diseases like cancer and viral reactivation. Recent research highlights include studies on chromatin landscape evolution in acute lymphoblastic leukemia, transcriptional stochasticity, and therapeutic resistance mechanisms in cancer cells. The lab collaborates on projects involving zinc finger design for genome editing and systems-level analysis of melanoma genetics. Lab activities emphasize interdisciplinary approaches, combining quantitative biology with clinical insights to advance regenerative medicine and cancer therapy strategies.
Doron Betel serves as an Assistant Professor at Weill Cornell Medicine's Graduate School of Medical Sciences, with affiliations in both the Physiology, Biophysics & Systems Biology and Computational Biology programs. He directs the Applied Bioinformatics Core (ABC), a central service group providing specialized computational and analytical support for biomedical research across multiple institutions. Dr. Betel's research focuses on developing computational genomic tools for studying human diseases and cellular development, with emphasis on integrative analyses of genomic and epigenomic data from high-throughput assays. His work addresses specific questions related to disease progression, treatment response, stem cell differentiation, and neurological processes through two closely interacting research groups: the Applied Bioinformatics Core and his independent research lab. The analysis of his recent publications reveals a strong emphasis on single-cell and spatial genomics, cross-species data integration, and machine learning applications in cancer immunology and neurodegenerative disease modeling. His research spans multiple high-impact areas including cancer immunotherapy, stem cell biology, diabetes research, and cardiovascular regeneration, with numerous publications in top journals like Nature, Cell, and Nature Immunology. Through the Applied Bioinformatics Core, Dr. Betel provides extensive analytical support across various genomic platforms including single-cell RNA-seq, spatial transcriptomics, ChIP-seq, ATAC-seq, and variant calling. The Core serves as a vital resource for researchers at Weill Cornell Medicine and the broader Tri-Institutional network, offering specialized analysis, computational pipelines, and training services. Dr. Betel maintains extensive collaborations with leading researchers including Lorenz Studer at MSKCC for stem cell and neurodegenerative disease research, Tuomas Tammela for cancer genomics, and multiple immunology researchers studying T cell function in autoimmunity and cancer. His work bridges computational methodology development with direct biomedical applications across multiple disease areas.
Dr. Anna Baldycheva is a Senior Lecturer in Electronic Engineering at the University of Exeter, within the College of Engineering, Mathematics and Physical Sciences. She leads the interdisciplinary STEMM Laboratory, focusing on applied R&D in smart materials, photonics, AI, and IoT. With prior research experience at MIT, Trinity College Dublin, and Tyndall National Institute, she has established herself as an internationally recognized innovator and entrepreneur in emerging technologies. PhD in Electronic and Electrical Engineering, Trinity College Dublin (2008–2012) BSc (Hons) in Physics, St. Petersburg State University (2003–2008) Postgraduate Certificate in Academic Practice, University of Exeter (2016–2017) Postgraduate Certificate in Technology Management, Smurfit Business School (2009–2010) Her research spans Nano-Engineering, Opto-Electronics, Photonics, AI, and IoT , with a strong emphasis on real-world applications. She pioneers work in fluid opto-electronics , graphene nanocoatings , and AI-driven emotion recognition and early cancer detection . Her lab develops smart composite materials for flexible electronics, e-textiles, and structural applications, integrating machine learning into healthcare, education, and communications systems. The recent publications highlight a strong trend toward applied interdisciplinary innovation , combining materials science with AI and photonics for healthcare diagnostics, energy-efficient computing, and educational technology. Her work frequently bridges fundamental physics with commercialization potential, as seen in spin-out technologies like GSurf and the Electronic-Nose for lung cancer detection. Fellow, Royal Microscopical Society (RMS) Fellow, Higher Education Academy (FHEA) Expert, Future and Emerging Technologies, European Commission Featured in Forbes and Forbes Tech Council Editor-in-Chief, InSTEMM Journal Associate Editor, Nature Scientific Reports and Discover Nano Trustee, Royal Microscopical Society Founder, STEMM Global Scientific Society Founder, It’s Her! Women in STEMM Initiative Dr. Baldycheva actively supervises PhD students and has secured industrial collaborations with organizations such as Qinetiq and Lumentum. She leads multiple outreach initiatives, including STEMM Junior for underprivileged children, and serves on the committee for the Jocelyn Bell Brunel PhD Scholarship. She has raised significant research funding through national and international grants, though specific grant names are not listed. She leads the STEMM Laboratory , a multidisciplinary research group with divisions in Smart Composite Materials, Machine Learning & AI, and Opto-Electronics & Photonics. The lab emphasizes industry collaboration and technology transfer, having produced a university spin-out (GSurf) and multiple media-highlighted innovations.
Xin Lu is the John M. and Mary Jo Boler Collegiate Associate Professor in the Department of Biological Sciences at the University of Notre Dame. She is a full member of the Harper Cancer Research Institute (HCRI), the Boler-Parseghian Center for Rare and Neglected Diseases (CRND), and the Tumor Microenvironment and Metastasis Program at the Indiana University Simon Comprehensive Cancer Center. Her research spans tumor immunology, immunotherapy, metastasis, and multi-omics, with a focus on prostate, breast, and rare cancers. Ph.D. in Molecular Biology, Princeton University (2004–2010) B.S. in Biological Sciences, Tsinghua University, China (2000–2004) Postdoctoral Fellow, Dana-Farber Cancer Institute and M.D. Anderson Cancer Center (2010–2016) Assistant to Associate Professor, University of Notre Dame (2017–Present) Dr. Lu's research investigates the molecular and cellular mechanisms of tumor-immune crosstalk, particularly the role of myeloid-derived suppressor cells (MDSCs) and neutrophils in promoting immunotherapy resistance. Her lab uses genetically engineered mouse models, functional genomics, single-cell and spatial transcriptomics, and high-throughput screening to uncover novel therapeutic targets. A major focus is on how cancer-cell-intrinsic oncogenic signaling shapes the immunosuppressive tumor microenvironment. Her recent publications reveal mechanisms such as Acod1-mediated ferroptosis resistance in neutrophils, Pygo2-driven immunosuppression in prostate cancer, and the efficacy of ketogenic diets in overcoming checkpoint blockade resistance. These studies span multiple disciplines including cancer biology, immunology, metabolism, epigenetics, and bioengineering, reflecting a highly integrative approach to immuno-oncology. Jane Coffin Childs Postdoctoral Fellow John M. and Mary Jo Boler Faculty Appointment Cluster Chair, Cellular & Molecular Biology, IBMS PhD Program Junior Chair, Boler-Parseghian Center for Rare and Neglected Diseases Dr. Lu mentors a diverse team of graduate students, postdoctoral fellows, and undergraduates. Her lab is actively recruiting and has secured funding from federal agencies and private foundations. She collaborates with chemists, bioengineers, and bioinformaticians to develop novel therapeutics, including antibody-drug conjugates, CAR-NK cells, and small-molecule inhibitors. Her lab also develops innovative platforms like mini-tumor chips for immunotherapy evaluation. Her lab maintains affiliations with multiple interdisciplinary centers including the Warren Family Center for Drug Discovery, Eck Institute for Global Health, and Berthiaume Institute for Precision Health, underscoring her collaborative and translational research vision.
Benjamin Simons is the Royal Society EP Abraham Professor and Herchel Smith Professor of Physics at the University of Cambridge. He serves as Director of the Gurdon Institute, Senior Group Leader at the Gurdon Institute, Principal Investigator at the Cambridge Stem Cell Institute, and member of the Theory of Condensed Matter physics group. He is also a Fellow of St. John's College, Cambridge. His research integrates quantitative approaches from physics and mathematics with experimental biology to investigate stem cell fate regulation in tissue development, maintenance, and cancer pathogenesis. Research focuses on: Stochastic cell fate decisions in epithelial tissues Self-organization principles in tissue morphogenesis Single-cell lineage tracing and gene expression analysis Mathematical modeling of stem cell dynamics Cancer initiation through stem cell reprogramming Publication analysis reveals consistent themes: spatial dynamics of stem cell niches, mechanical regulation of cell fate, computational modeling of tissue organization, and evolutionary principles in cancer development. Recent work emphasizes in vivo lineage tracing, single-cell omics, and interdisciplinary approaches bridging physics and biology. Scientific Awards: Fellow of the Royal Society (FRS) Fellow of the Academy of Medical Sciences (FMedSci) Leads an interdisciplinary research group combining wet-lab experiments (lineage tracing, single-cell genomics) with theoretical modeling. Research supported by EPSRC, MRC, Wellcome Trust, Cancer Research UK, and Royal Society grants. Current projects include gliomagenesis mechanisms, spermatogenic wave regulation, and injury response pathways co-opted in cancer.
Nathaniel Nucci is an Associate Professor at Rowan University's College of Science & Mathematics, jointly appointed in the Department of Biological & Biomedical Sciences and Physics & Astronomy. His research bridges biophysics, structural biology, and nanotechnology to understand protein behavior in confined environments. Education Ph.D., Biochemistry and Molecular Biophysics, University of Pennsylvania M.S., Biochemistry and Molecular Biology, University of New Hampshire B.S., Biochemistry and Molecular Biology, University of New Hampshire Research Interests Dr. Nucci's lab focuses on: Protein biophysics in crowded/confining environments Reverse micelle technology for biomolecular studies Hydration dynamics of proteins (NMR-based methods) Structural biology of disease-related proteins (PHDs, p53) Drug delivery systems for protein therapeutics Nanoparticle synthesis with protein conjugation Research Trends His recent publications demonstrate expertise in using reverse micelles to study: Protein structural stability under confinement Hydration dynamics of therapeutic proteins Microenvironmental effects on phase-separating proteins Conformational changes in GPCRs Interfacial interactions in biomolecular systems Scientific Awards Gary J. Hunter Excellence in Mentoring Award (2024) College of Science and Mathematics Excellence in Academic Student Support (2022) Teaching Philosophy Emphasizes applied and experiential learning, integrating recent scientific discoveries into classroom practice and promoting hands-on scientific investigation.
Professor Martin Peifer is a computational cancer genomics researcher at the University of Cologne, where he leads the Department of Translational Genomics. He serves as Principal Investigator of the Peifer Lab, which focuses on developing computational methods to analyze cancer genome sequencing data. His work is deeply integrated with the Center for Data and Simulation Science and he is an active member of the International Cancer Genome Consortium and the Pan-Cancer Analysis of Whole Genomes project. Peifer's research interests center on computational approaches to understanding cancer biology, with particular emphasis on tumor evolution and genome instability mechanisms. His lab develops methods to analyze somatic genome alterations including point mutations, copy number changes, and rearrangements. They also create computational tools for integrative genome analyses, tumor evolution reconstruction, and single-cell sequencing data analysis (both RNA and DNA). His interdisciplinary team applies high-performance computing and machine learning to interpret complex cancer sequencing data, aiming to better understand tumorigenesis, clonal evolution, and therapy resistance. Analysis of Peifer's extensive publication record reveals a strong focus on neuroblastoma and lung cancer genomics, with particular attention to tumor evolution patterns and genomic instability mechanisms. His work spans multiple cancer types but maintains consistent themes of computational methodology development and application to understand cancer progression and treatment resistance. The publications demonstrate increasing sophistication in analyzing intra-tumor heterogeneity and clonal dynamics over time. Peifer leads an active research group including postdoctoral fellows (Joel Kaufmann, Dr. Stephanie Pabel, Agnieszka Rumińska) and PhD students (Magdalena Seiffert, Justinas Valiulis). His lab is involved in the Collaborative Research Center 1399 focused on Mechanisms of Drug Sensitivity and Resistance in Small Cell Lung Cancer, indicating significant grant funding and collaborative research efforts. The Peifer Lab operates at the intersection of computational biology and cancer research, maintaining an interdisciplinary approach that combines bioinformatics, machine learning, and high-performance computing to address complex questions in cancer genomics. Their work has significant implications for understanding cancer evolution and developing more effective treatment strategies.
